| References: |
BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).BLU9931 is exquisitely selective for FGFR4 versus other FGFR family members and all other kinases. BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification. Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor. For the detailed information of BLU-9931, the solubility of BLU-9931 in water, the solubility of BLU-9931 in DMSO, the solubility of BLU-9931 in PBS buffer, the animal experiment (test) of BLU-9931, the cell expriment (test) of BLU-9931, the in vivo, in vitro and clinical trial test of BLU-9931, the EC50, IC50,and affinity,of BLU-9931, For the detailed information of BLU-9931, the solubility of BLU-9931 in water, the solubility of BLU-9931 in DMSO, the solubility of BLU-9931 in PBS buffer, the animal experiment (test) of BLU-9931, the cell expriment (test) of BLU-9931, the in vivo, in vitro and clinical trial test of BLU-9931, the EC50, IC50,and affinity,of BLU-9931, Please contact DC Chemicals. |
